Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000403 · ClinicalTrials.gov registry record · Phase 3

Doxycycline and OA Progression

A Phase 3 study, sponsored by Indiana University.

Completed
Registry status
Phase 3
Development phase
432
Enrollment target

NCT00000403: Completed Phase 3 study, sponsored by Indiana University.

NCT00000403 is a Phase 3 study that has completed, run by Indiana University. The registered enrollment target is 432 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (44% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000403, a Phase 3 study, has completed, sponsored by Indiana University.

COMPLETED
Registry status
Phase 3
Development phase
432 participants
Enrollment target

Study Summary

This study will determine whether doxycycline decreases the severity or rate of progression of osteoarthritis (OA) in the knee. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most popular agents used to treat OA, but elderly women, in whom OA is especially common, are at greatest risk of developing serious side effects from NSAIDs. Our study targets overweight middle-aged women who have OA in one knee. Half of the 432 study participants will receive the treatment (doxycycline) and half will receive a placebo (inactive pill). Treatment with doxycycline (or placebo) will last 30 months, and participants and researchers will not know who is receiving doxycycline and who is receiving placebo until the end of the study. We will look for narrowing of the joint space in the knee that was not affected by OA at the start of the study. Joint space narrowing is a sign of OA. We will also use questionnaires to evaluate participants' symptoms and functioning.

Interventions

  • DRUG Doxycycline

Trial Details

FieldValue
Enrollment Target 432 participants
Start Date 1996-09
Est. Completion 2001-07
Phase Phase 3
Indiana University

890 total trials

What the finished NCT00000403 record still lists

NCT00000403 is an interventional study that assigns participants to a tested intervention. The registered 432 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (44% lower).

The record links to 0 conditions, and to 1 intervention - of which Doxycycline is the first listed.

NCT00000403 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00000403 about?

NCT00000403 is a clinical study titled "Doxycycline and OA Progression". This study will determine whether doxycycline decreases the severity or rate of progression of osteoarthritis (OA) in the knee. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most popular agents used to treat OA, but elderly women, in whom OA is especially common, are at greatest risk of deve...

What is the current status of trial NCT00000403?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 432 participants. The study started on 1996-09. Estimated completion is 2001-07.

What interventions are being tested in trial NCT00000403?

The interventions under investigation include: Doxycycline (DRUG).

Who is sponsoring clinical trial NCT00000403?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00000403's enrollment target sits among peer trials

432 876th of 2000 higher than 1,124 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05271240 · 432 participants · Phase 3

    Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM

  • NCT05365815 · 432 participants · NA

    Melanated Group Midwifery Care (MGMC)

  • NCT05499507 · 432 participants · NA

    The Path to Optimal Black Maternal Heart Health: Comparing Two CVD Risk Reduction Interventions (Change of HEART)

  • NCT05806164 · 432 participants · Phase 4

    Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00000403, the US trial registry maintained by the National Library of Medicine. NCT00000403 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.